San Diego-dependent Viking Therapeutics marked by itself as a significant competitor inside the weight loss drug marketplace in February soon after revealing promising information from a mid-phase demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when presented for a weekly injection and in March t